Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes.
Alexander J MoodyMarjorie Molina-WilkinsGeoffrey D ClarkeAurora MerovciCarolina Solis-HerreraEugenio CersosimoRobert J ChiltonPatricia IozzoFrancesco RubinoMuhammad A Abdul-GhaniMuhammad Abdul-GhaniPublished in: Diabetes, obesity & metabolism (2022)
Pioglitazone reduced EAT and PAT areas and improved left ventricular (LV) diastolic function in T2DM. EAT and PAT are inversely correlated (PAT less strongly) with LV diastolic function and both EAT and PAT are inversely correlated with measures of insulin sensitivity.